ZA200108378B - Use of cell membrane penetrating indigoid bisindole derivatives. - Google Patents
Use of cell membrane penetrating indigoid bisindole derivatives. Download PDFInfo
- Publication number
- ZA200108378B ZA200108378B ZA200108378A ZA200108378A ZA200108378B ZA 200108378 B ZA200108378 B ZA 200108378B ZA 200108378 A ZA200108378 A ZA 200108378A ZA 200108378 A ZA200108378 A ZA 200108378A ZA 200108378 B ZA200108378 B ZA 200108378B
- Authority
- ZA
- South Africa
- Prior art keywords
- carcinoma
- substance
- composition
- derivatives
- tumor
- Prior art date
Links
- 210000000170 cell membrane Anatomy 0.000 title claims description 7
- 230000000149 penetrating effect Effects 0.000 title claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 23
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical class N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 17
- MLCPSWPIYHDOKG-BUHFOSPRSA-N (3e)-3-(2-oxo-1h-indol-3-ylidene)-1h-indol-2-one Chemical compound O=C\1NC2=CC=CC=C2C/1=C1/C2=CC=CC=C2NC1=O MLCPSWPIYHDOKG-BUHFOSPRSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 235000000177 Indigofera tinctoria Nutrition 0.000 claims description 8
- 229940097275 indigo Drugs 0.000 claims description 8
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 201000008275 breast carcinoma Diseases 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 201000009546 lung large cell carcinoma Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 201000001531 bladder carcinoma Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000010174 renal carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 4
- -1 3-phenylindol-2-yl Chemical group 0.000 claims description 3
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910052740 iodine Chemical group 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 125000000565 sulfonamide group Chemical group 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 description 22
- 229910052799 carbon Inorganic materials 0.000 description 22
- 229910052739 hydrogen Inorganic materials 0.000 description 22
- 229910052757 nitrogen Inorganic materials 0.000 description 22
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 238000000160 carbon, hydrogen and nitrogen elemental analysis Methods 0.000 description 11
- 238000001819 mass spectrum Methods 0.000 description 10
- 239000013543 active substance Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 230000001413 cellular effect Effects 0.000 description 9
- JKMBMIMLVFMXRW-LYYFRFARSA-N epicocconone Chemical compound C1=C2C[C@@H](CO)OC=C2C(=O)[C@]2(C)C1=C(C(/O)=C/C(=O)/C=C/C=C/C=C/C)C(=O)O2 JKMBMIMLVFMXRW-LYYFRFARSA-N 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 210000004379 membrane Anatomy 0.000 description 8
- 241001062009 Indigofera Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- JXDYKVIHCLTXOP-UHFFFAOYSA-N isatin Chemical compound C1=CC=C2C(=O)C(=O)NC2=C1 JXDYKVIHCLTXOP-UHFFFAOYSA-N 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000334154 Isatis tinctoria Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000000719 anti-leukaemic effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- HBDSHCUSXQATPO-BGBJRWHRSA-N indirubin-3'-monoxime Chemical compound O=C/1NC2=CC=CC=C2C\1=C\1/C(=N/O)/C2=CC=CC=C2N/1 HBDSHCUSXQATPO-BGBJRWHRSA-N 0.000 description 3
- PCKPVGOLPKLUHR-UHFFFAOYSA-N indoxyl Chemical compound C1=CC=C2C(O)=CNC2=C1 PCKPVGOLPKLUHR-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 231100000338 sulforhodamine B assay Toxicity 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- 241000219193 Brassicaceae Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- JBOPQACSHPPKEP-UHFFFAOYSA-N Indoxyl acetate Chemical compound C1=CC=C2C(OC(=O)C)=CNC2=C1 JBOPQACSHPPKEP-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- AOHZJKSTSDMBIZ-UHFFFAOYSA-N chembl111433 Chemical compound C1=CC=C2C(=O)C(C3=C(O)NC4=CC=C(C=C43)C)=NC2=C1 AOHZJKSTSDMBIZ-UHFFFAOYSA-N 0.000 description 2
- FQCPPVRJPILDIK-UHFFFAOYSA-N chembl126077 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC=CC=C21 FQCPPVRJPILDIK-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- XVARCVCWNFACQC-RKQHYHRCSA-N indican Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=CC=C12 XVARCVCWNFACQC-RKQHYHRCSA-N 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 2
- 238000003210 sulforhodamine B staining Methods 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 241000207965 Acanthaceae Species 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 244000301682 Heliotropium curassavicum Species 0.000 description 1
- 235000015854 Heliotropium curassavicum Nutrition 0.000 description 1
- 240000004343 Indigofera suffruticosa Species 0.000 description 1
- 244000178827 Leea guineensis Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000528415 Moana Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930182559 Natural dye Natural products 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000257673 Strobilanthes cusia Species 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000009937 brining Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- XMPHNZMDLSUDQI-UHFFFAOYSA-N chembl173682 Chemical compound C1=CC=C2C(=O)C(C=3C4=CC(Br)=CC=C4NC=3O)=NC2=C1 XMPHNZMDLSUDQI-UHFFFAOYSA-N 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 101150030658 coaE gene Proteins 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- BXFFHSIDQOFMLE-UHFFFAOYSA-N indoxyl sulfate Natural products C1=CC=C2C(OS(=O)(=O)O)=CNC2=C1 BXFFHSIDQOFMLE-UHFFFAOYSA-N 0.000 description 1
- XVARCVCWNFACQC-UHFFFAOYSA-N indoxyl-beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CNC2=CC=CC=C12 XVARCVCWNFACQC-UHFFFAOYSA-N 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- IVTPKBBAFISNAL-UHFFFAOYSA-N n,n'-bis(2-benzoylphenyl)oxamide Chemical compound C=1C=CC=C(C(=O)C=2C=CC=CC=2)C=1NC(=O)C(=O)NC1=CC=CC=C1C(=O)C1=CC=CC=C1 IVTPKBBAFISNAL-UHFFFAOYSA-N 0.000 description 1
- 239000000978 natural dye Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229940112877 olux Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Indole Compounds (AREA)
Description
: "Use of cell membrane penetrating Indigoid bisindole derivatives"
The present invention relates to the use of cell membrane penetrating indigoid bisindole derivatives for the manufacture of a medicament for the treatment of human solid cancers.
Indigoid bisindoles comprise a spectrum of natural dye stuffs. Many of these can be obtained from plants. Accordingly, indirubin, indigo and isoindigo are natural products which can be obtained from different plants: namely, Baphicacanthus cusia (Acanthaceae), Indigofera suffruticosa (Fabaceae), Isatis indigotica (Brassicaceae) and others. Indican, a glycoside which is found in plants, gives glucose and 3-hydroxyindole due to acidic or enzymatic hydrolysis. 3-Hydroxy- ) indole is converted by air-oxidation into indigo and its isomers. indigo naturalis : (Chinese: quingdai) is the natural blue dye obtained from plant material, e.g. ) Isatis indigotica (Brassicaceae). Indirubin, an isomer of indigo, can be found in
Indigo naturalis in an amount of up to 60% (Falbe J. & Regitz M., Rémpp
Chemie Lexikon (1992), 9. Aufl., Stuttgart, Georg Thieme Verlag). It occurs also in Isatis tinctoria in an amount of up to 5% which is indigenous to Central
Europe (Gelius R., Z. Chem., 20, (1980), 340-341). Derivatives of indirubin are known for a long time as dyes of low persistence. indigo naturalis is reported to be used in traditional Chinese medicine as a haemostatic, anti-pyretic, anti-inflammatory and sedative agent in the treatment of bacterial and viral infections. Antileukemic effects of Indigo naturalis have also been reported, with indirubin being the effective principle (Ji X. et al., Acta
Pharm. Sin., 16, (1981), 146-148; Gan W. J. etal., J. Hematol., 6, (1985), 611-613). In spite of its anti-leukaemic activity, however, indirubin dissolves only poorly in water and is therefore not readily resorbed. Recently, the antileukemic activity of some better soluble indirubin derivatives has been n ] reported (Ch. Li et a., Bull. Chem. Soc. Jpn. 69, 1621-1627 (1996)).
However, indigoid bisindole or its derivatives have never been investigated with respect to solid tumors, in particular human solid tumors, and furthermore, the problem of the poor solubility resulting in a poor resorption has not been sufficiently solved yet.
Thus, the technical problem underlying the present invention is to provide new active substances which can be used in the treatment of human solid tumors and metastasis thereof. Furthermore, the resorption of said substances should be improved in order to improve their in vivo anti-tumor activity.
The solution to the above technical problem is achieved by the embodiments characterized in the claims. :
In particular, the present invention relates to the use of cell membrane penetra- ting indigoid bisindole derivatives for the manufacture of a medicament for the treatment of human solid tumors and metastasis thereof wherein the indigoid derivatives are selected from indigo, bis{3-phenylindoi-2-yl), isoindigo and ) indirubin derivatives, the latter represented by the following formula (1): rR!
Pe (1 d wherein, when X represents an oxygen atom, R' represents a hydrogen atom, a halogen atom, a -NO, group, a methyl group, a sulfonamide group or SO,-NH-
CH,CH,-OH; and wherein, when X represents NOH, R' represents a hydrogen atom or an iodine atom.
The above indigoid bisindole derivatives can also be employed in the form of their physiologically acceptable salts. Furthermore, the indigoid bisindole derivatives according to the present invention may also be chemically coupled to masking agents as described e.g. in German patent application DE-A-38 27 488 which function to carry the anti-tumor active substances to the tumor.
In the following, the indigoid derivatives selected from indigo, isoindigo and indirubin derivatives according to the present invention are also addressed to as "anti-tumor active compounds according to the present invention”.
According to the present invention the terms "cell membrane penetrating” and "cell resorbable” mean the ability of the indigoid bisindole derivatives to be taken up by the tumor cell through the cellular membrane.
The term "human solid tumors" according to the present invention preferably includes carcinomas, melanomas, adenomas, sarcomas, lymphomas, 156 neuroblastomas, teratomas, astrocytomas, glioblastomas and mesotheliomas.
Specific examples are mammary carcinoma, large-cell lung carcinoma, small-cell lung carcinoma, lung epidermoid and adenocarcinoma, colorectal carcinoma, } bladder carcinoma, ovarian carcinoma, pancreatic carcinoma, renal carcinoma, prostatic carcinoma, head and neck carcinomas, melanomas, cervical car- cinomas, osteosarcoma and the like.
The above identified indigoid bisindole derivatives of the present invention can be formulated into pharmaceutical compositions which contain optionally a pharmaceutically acceptable carrier and/or diluent. Said pharmaceutical compositions can be applied e.g. orally, topically, intravenously, intraperitoneally, subcutaneously and rectally in pharmaceutically effective amounts.
One general problem in the field of pharmacology is the formulation of pharmaceutically active substances in pharmaceutical compositions which can be applied to a human body. Since most physiological fluids are waterbased, the pharmaceutically active substances should be soluble in water and/or a water mixable solvent wherein the latter of course has to be physiologically acceptable in small concentrations, such as ethanol. Furthermore, pharmaceutically active substances which are taken orally have to be resorbed into surface of the human body - including the gastrointestinal mucous membrane- or, in case of an appli- cation via syringe, e.g. intraperitoneal or intravasal, have to be resorbed through the cellular membranes of the of destination cells, specifically into the tumor cells.
According to the present invention it has been found that in case of the indigoid bisindole derivatives according to the present invention, a good solubility is not the only prerequisite guaranteeing a good anti-tumor activity /n vivo as it will become apparent by the Examples and Comparative Examples shown below. An important factor for the anti-tumor activity of indigoid bisindole derivatives is their, ability to penetrate the cellular membranes of the tumor cells. Cellular membranes are composed of lipids and compose a rather non-polar medium.
Therefore, substitution with extremely polar groups such as the sulfonate group on the one hand improves the water solubility of a compound but on the other . hand hinders or even prohibits the resorption of anti-tumor active substances into a tumor cell. Thus, anti-tumor active substances which show good anti- . tumor activities under certain in vitro conditions, have to be rejected because of not showing any activity when tested using intact cells or in vivo.
Therefore, in the following Examples the testing of the anti-tumor active sub- stances are tested by in vitro tests using intact tumor cells and, additionally, in vivo tests. Furthermore, a comparison of the activity test results and the tests evaluating the ability to penetrate cellular membranes shows that indigoid bisindole compounds which exhibit a good cell-penetrating ability also show good to excellent anti-tumor activity.
The Figures show:
Fig. 1 is a graph which shows the development of the relative tumor volume with time during chemotherapy of LXFL 528/17 with indigoid bisindole deriva- tives according to the present invention (compounds according to Examples 1,
© WO 00/61124 PCT/EP00/03210 v ~ 5 4 and 6). The anti-tumor active substances according to the present invention were applied intraperitoneally to nude mice in doses and according to the schedule as described below in Table 4. Compared to the vehicle control, all compounds significantly inhibited the tumor growth.
Fig. 2 is a graph which shows the relative body weight change of the tested nude mice with time during chemotherapy of LXFL 529/17. 5-Methylindirubin (Example 6) at a dosage of 100 mg/kg up to 300 mg/kg showed very high anti- tumor activity (Fig. 1 and Fig. 3) without any significant reduction of body weight (Fig. 2 and Fig. 4) thus demonstrating high anti-tumor activity without significant toxicity.
Fig. 3, Fig. 5 and Fig. 7 are graphs which show the relative tumor volume versus the time during the chemotherapy of LXFL 529/17 with other indigoid bisindole derivatives according to the present invention (compounds according to Exam- ples 8, 9, 10 and 14).
Fig. 4, Fig. 6 and Fig. 8 are graphs which show the relative body weight change of the tested nude mice with time during chemotherapy of LXFL 529/17 using said other indigoid bisindole derivatives according to the present invention.
The present invention is explained in detail by the following examples and comparative examples by which also further advantages of the present invention will become apparent. 1. Synthesis of the indigoid bisindole derivatives
Example 1 (Indirubin)
To a solution of 0.42 g {2.4 mmol) of indoxyl acetate in 20 ml methanol! under argon 0.35 g (2.4 mmol) of isatin and 0.55 g (5.2 mmol) of sodium carbonate are added. The mixture is stirred for 30 min at ambient temperature. After 24 h standing at ambient temperature, the reaction mixture is filtered off. The preci- pitate is washed with little methanol and water until the filtrate shows a neutral
6 a pH. Residual water is removed by storage in an evacuated exsiccator over potassium hydroxide. Recrystallisation from ethanol or pyridine gives deep purple crystals (Russell G.A., Kaupp G. (1969), J. Am. Chem. Soc., 91, 3851-9, modified).
Yield: 0.51 g (81%), fine, deep-purple needles, Fp: 341-343°C
CHN-analysis: (C,sH;oN,0,); MW: 262.26 g/mol; calc.: 73.3% C, 3.8% H, 10.7% N; found: 73.2% C, 4.0% H, 10.6% N mass spectrum: m/z = 262: (M*, 100%), 234: (43%), 205 (25%), 158 (3%), 131 (4%), 103 (7%), 76 (3%) "H-NMR and '*C-NMR-spectrum are in accordance with the proposed structure.
IR-spectrum: 3340 cm: v (N-H), 1710 cm™: v (3°-C=0), 1650 cm™: v (2-
C=0), 1590 cm’: v (C=C, aryl), 1450 cm™: v (C=C, aryl), 745 cm™: v (aryl with four neighbouring H-atoms).
UV/Vis-spectrum (DMSO): 290 nm, 363 nm, 383 nm (shoulder), 551nm.
Essentially the same synthetic procedure was applied for the following Examples 2t0 9, 12, 13 and Comparative Examples 1 and 2:
Example 2 (5-lodoindirubine)
Yield: 80%, fine, deep-purple needles, Fp: 334-335°C (decomposition);
CHN-analysis (C,sHoIN,0,); MG = 388.16 g/mol; calc.: 49.5% C, 2.3% H, 7.2% N; found.: 49.7% C, 2.5% H, 7.1% N;
Mass spectrum: 388 (M*, 100%), 360 (3%), 269 (9%), 261 (6%), 233 (16%), 205 (16%), 128 (1%); 'H-NMR- and *C-NMR-spectrum are in accordance with the proposed structure.
UV/Vis-spectrum (DMSO): 370 nm, 386 nm (shoulder), 555 nm.
Example 3 (5-Bromoindirubin)
Yield: 70%, fine, deep-purple needles;
CHN-analysis (C,¢HgBrN,0O,); MG = 341.16 g/mol, calc.: 56.3% C, 2.7% H, 8.2% N;
© WOo00/61124 PCT/EP00/03210 found 56.4% C, 2.7% H, 8.2% N;
Mass spectrum: 342(M*, 100%), 340 (M*, 98%), 314 (18%), 262 (64%), 233 (34%), 205 (81%), 177 (10%); 'H-NMR- and '*C-NMR-spectrum are in accordance with the proposed structure. a
Example 4 (5-Chloroindirubin)
Yield: 95%, fine, deep-purple needles;
CHN-analysis (C,gHCIN,O,); MG = 296.70 g/mol; calc.: 49.5% C, 2.3% H, 7.2% N; found: 49.7% C, 2.5% H, 7.1% N;
Mass spectrum: m/z = 296 (M*, 100%), 268 (39%), 239 (8%), 233 (35%), 205 (50%), 177 (7%), 153 (6%), 137 (7%), 77 (7%), 120 (4%), 102 (6%), 77 (7%). 'H-NMR- and '*C-NMR-spectrum are in accordance with the proposed structure.
Example 5 (5-Fluoroindirubin) :
Yield: 92%, fine, deep-purple needles;
CHN-analysis (C;gHsFN,0,), MG = 280.25 g/mol, calc.: 68.6% C, 3.2% H, 9.9% N; found: 68.0%C, 3.2% H, 9.9% N;
Mass spectrum: m/z = 281 (M* +H™*, 19%), 280 (M*, 100%), 252 (73%), 223 (32%), 176 (6%), 140 (7%), 121 (13%), 94 (4%), 76 (12%), 77 (7%), 57 (4%), 44(15%). 'H-NMR- and '3C-NMR-spectrum are in accordance with the proposed structure.
Example 6 (5-Methylindirubin)
Yield: 92%, fine, deep-purple needles;
CHN-analysis (C,,H,,N,0,), MG = 276.28 g/mol, calc.: 73.9% C, 4.4% H, 10.1% N; found: 73.8%C, 4.3% H, 10.2% N;
Mass spectrum: m/z = 276 (M*, 100%), 261 (10%), 248 (47%), 247 (53%), 220 (6%), 219 (18%), 205 (7%), 171 (4%), 165 (10%), 138 (4%), 133 (15%), 104 (7%), 77 (7%);
8 u , 'H-NMR- and '3C-NMR-spectrum are in accordance with the proposed structure.
Example 7 {5-Nitroindirubin)
Yield: 88%, fine, deep-purple needles;
CHN-analysis (C,sHsN;0,), MG = 307.26 g/mol; calc.: 62.5% C, 3.0% H, 13.7% N; found: 62.4%C, 3.0% H, 13.3% N;
Mass spectrum: m/z = 307 (M*, 5%), 276 (10%), 262 (100%), 234 (23%), 205 (22%), 158 (6%), 131 (10), 104 (19%), 76 (12%), 50 (6%). '"H-NMR- and '3C-NMR-spectrum are in accordance with the proposed structure.
Example 8 (indirubin-3’-oxime)
Indirubin-3’-oxime was synthesized by reaction of indirubin with hydroxylamine hydrochloride in a pyridine solution (Farbwerke vorm. Meister Lucius & Brining in Hoechst a.M., Patentschrift des Reichspatentamtes Nr. 283726 (1913). *C- : NMR-spectroscopy revealed the location of the hydroxyimino residue in 3'-
Position (6(C2) = 171.05 ppm: &(C3') = 145.42 ppm; DMSO-dg, RT) oo
Yield: 90 %, red crystals;
CHN-analysis (C,gH;;N;0,), MG = 277.30 g/mol; calc.: 69.3% C, 4.0% H, 15.2 % N; found: 69.0% C, 4.0% H, 14.9% N; 'H-NMR- and '*C-NMR-spectrum are in accordance with the proposed structure.
Example 9 (5-lodoindirubine-3’-oxime)
Indirubin-3’-oxime was synthesized by reaction of 5-lodoindirubine with hydroxylamine hydrochloride in a pyridine solution. 3C-NMR-spectroscopy revealed the location of the hydroxyimino residue in 3’-Position (8(C2) = 170.25 ppm; 8(C3’) = 151.52 ppm; DMSO-d¢, RT)
Yield: 90 %, red crystals;
CHN-analysis {C,gH,0IN;0,), MG = 403,20 g/mol; calc.: 47,7%C, 2,5% H, 10,4% N; found: 47,1% C, 2,5% H, 10,1% N; 'H-NMR- and 3C-NMR-spectrum are in accordance with the proposed structure.
Wooue24 PCT/EP00/03210 . IN 9
H
NO
Example 10 {Isoindigo) o”™N g
H
Isoindigo was synthesized by reaction of oxindole with isatin in acetic acid with addition of hydrochloric acid (Wahl A., Bayard P., Comptes Rendues
Hebdomadaires des Seances de L’Academie des Sciences, 148, (1909), 716- 719).
Yield: 84%, crystalline, brown substance;
CHN-analysis (C,¢H,oN,0,), MG = 262.26 g/mol; calc.: 73.3% C, 3.8% H, 10,7% N; found: 73.0% C, 3.8% H, 10.9% N;
Mass spectrum: m/z = 262 (M*, 100%), 234 (85%), 220 (5%), 205 (18%), 190 (4%), 177 (5%), 151 (5%), 132 (17%), 103 (6%), 76 (4%), 32 (26%). } 'H-NMR- and '*C-NMR-spectrum are in accordance with the proposed structure. o
NH
Example 11 (Indigo) : .
Oo
Chemical grade indigo was purchased by Fluka Chemie AG.
Example 12 (indirubin-5-suifonamide) 'H-NMR- and 3*C-NMR-spectrum are in accordance with the proposed structure.
Example 13 (Indirubin-5-sulfone(2-hydroxyethyllamide 'H-NMR- and "*C-NMR-spectrum are in accordance with the proposed structure.
Example 14 (Bis(3-phenylindol-2-vi))
To a cooled solution of 2-aminobenzophenone in LC) dichloromethane and pyridine under inert gas, a solution of oxaly! chloride in dichloromethane is ) \ NH $ dropped. After completion of the reaction, 0.5 n NH \ hydrochloric acid is added, the formed preci- pitate is filtrated off and washed subsequently (2) with 0.5 n hydrochloric acid, a solution of sodium hydrogencarbonate and water. The obtained product (N,N’-bis(2-benzoylphenyl)-oxamide), zinc dust and titanium(lil)chioride are suspended in dimethoxyethane and heated to reflux.
After heating for 3 h, the mixture is cooled to ambient temperature and the : precipitate is filtrated off and washed with ethyl acetate. The crude product is purified using column chromatography (silica gel), then dissolved in ethyl acetate and precipitated in form of white crystals by adding petrol ether.
CHN-analysis (C,gH,oN,;), MG = 384.48 g/mol; calc.: 87.5%C, 5.2% H, 7.3% N; found: 87.3% C, 5.3% H, 7.3% N; : 'H-NMR- and *C-NMR-spectrum are in accordance with the proposed structure.
Comparative Example 1 (Indirubin-5-sulfonic acid) :
Yield: 76%, crystalline, deep-purple substance;
Mass spectrum: 388 (M*, 100%), 360 (3%), 269 (9%), 261 (6%), 233 (16%), 205 (16%), 128 (1%). 'H-NMR- and '*C-NMR-spectrum are in accordance with the proposed structure.
Comparative Example 2 (Indirubin-3’-oxime-5-sulfonic acid)
Yield: 76%, crystalline, deep-purple substance;
Mass spectrum: 388 (M*, 100%), 360 (3%), 269 (9%), 261 (6%), 233 (16%), 205 (16%), 128 (1%). 'H-NMR- and '3*C-NMR-spectrum are in accordance with the proposed structure.
Table 2 summarizes the structures of the indirubin compounds of Examples 1 to 9 and Comparative Examples 1 and 2.
Table 1
R1 » oe
NG NH
6)
Gramps oompownd | RX i Inder 0000] 00W | 0 2 [Swedomdwbn | 1 | 0 [3 [seromandiubn —& [0 5-Chloromdirubin IC EC 5 [stueomann | FF | o 6 [5-Methyindmbin on | 0 5-Niwraindinubin Wo, | o [8 [mdnbmdoume |W | Now [6 [Siodoindiubine3 oxime I
A I RR
[172 [indubnssufonamide sow, [0] [13 |Indirubin-5-sulfone{2-hydroxyethyllamide SO,-NH-CH,CH,0H | O
Bis(3-phenyindol-2-y) —
Comparative Examples
T [indrubin5-suifonic acd [som | o [2 |indirubin-3"-oxime-5-sulfonic acid oo 2. Cellular uptake into LXFL 529L cells
The compounds of Examples 1, 6 and 8 and Comparative Examples 1 and 2 were investigated with respect to their ability to penetrate LXFL 529L cells having the passage numbers P23 to P39. The results are shown in Table 2. The amounts of the substances taken up by the cells are given depending on the concentration of the substance within the incubation medium. The time of incubation was 2 hours in all of the experiments. Furthermore, the distribution of the substance which was taken up by the cells in the cytosol and the cellular organelles (particular) was estimated and is given in the intermediate column of
Table 2. Tumor cell growth inhibition was determined by the sulfo-rhodamine B assay (SRB assay) according to Skehan et al., J. Natl. Cancer Institute 82, pages
1107 - 1112 (1990). Incubation was conducted for three days in serum containing medium. Tumor cell lines tested were a large-cell lung carcinoma xenograft line LXFL 529 L and the mammary carcinoma line MCF-7. Results are given as IC, [uM] corresponding to the concentration of compounds inducing 50 % growth inhibition, compared to vehicle treated control.
Table 2 concentra- | amount of distribution Tumor cell growth tion of substance inhibition (SRB-assay) incubation | within the [%] ICs, cells WM]
CEE LED protein] organelles ) 10 0.15+0.08 7+5.7 93+5.7 9.9+0.1 4.0£2.0
Rl FE i Fo ll
Example 6 0.52+0.1 1310.7 87+0.7 7.5x0.5 4810.5 il pny i ll
Example 8 10 0.16 +£0.01 43+14.1 | 57+14.1 3.0+£0.5 3.3+0.4
Comparative | 10 < 0.02 > 100 > 100
Pel FR RN A i ll
Comparative < 0.05 > 100 > 100
Fl SE GS Fl
The compounds according to the Examples 1, 6 and 8 were all taken up by the tumor cells. The ability of the compound according to Example 6 to penetrate the cellular membrane is substantially improved compared to that of the parent compound indirubin (Example 1). The uptake of the compound according to
Example 8 is also slightly improved compared to the non-substituted indirubin (Example 1).
The compounds of Comparative Examples 1 and 2 were essentially not taken up by the cells although these compound are well soluble in physiological solutions.
Obviously, the sulfonate group hinders the penetration through the cellular membrane. Furthermore, referring to Comparative Example 2, this detrimental
© WO 00/61124 + PCT/EP00/03210 effect cannot be compensated by the introduction of an oxime group. 3. Evaluation of the anti-tumor activity
The anti-tumor activity of the compounds was evaluated via a colony-forming- assay as described e.g. by D. P. Berger et al. in Annals of Oncology 1, pages 333-341 (1990), "The clonongenic assay with human tumor xenografts, evalua- tion, predictive values and application for drug screening”.
The experiments were conducted using various tumor cell lines, in particular mammary carcinoma (MAXF) , lung adenocarcinoma (LXFA), large-cell lung carcinoma (LXFL), small-cell lung carcinoma (LXFS), colon carcinoma (CXF), melanoma (MEXF), pancreatic carcinoma (PAXF), renal carcinoma (RXF), ovarian carcinoma (OVXF) and bladder carcinoma (BXF).
The IC,o-values and ICg,-values, respectively, define the concentration of a pharmaceutically active compound causing 70 % and 50 %, respectively, reduction of colony formation compared to the untreated control. Therefore,
ICs- and IC5o-values serve to demonstrate the anti-tumor activity of a pharmaceutically active compound wherein low IC,- and/or 1Cg-values demonstrate a superior anti-tumor activity. According to the present invention, the 1C,,-value preferably is 20 4M or lower, more preferably 10 uM or lower.
Table 3 shows the anti-tumor activity of the compounds according to the
Examples and Comparative Example 1. The compounds according to the inven- tive Examples show good to excellent anti-tumor activity against various types of tumor cell lines. The compound according to Comparative Example 1 does not exhibit an anti-tumor activity against any of the tumor lines. This behaviour is in accordance with the lacking ability of this substance to penetrate cellular mem- branes as demonstrated in Table 2, above.
Surprisingly, small variations in the substitution pattern result in remarkable changes in the anti-tumor activity profile. However, almost all compounds according to the Examples exhibit good anti-tumor activity against mammary carcinoma.
. ~ 15
Rad pu
[2]
Ey e] 2 ™ ™ ~ flo 8g sg. ¢| 8.3 |. 28 ¢ |. 8s 388 - Nx — 0 xDUXI xd Xwx Xo wX X= XX0~- w- NL lac jac to Lolo TI [Ty o TE XX [ATP X]aiEXa [EXXAXN|EXX|alXxX o OO L | E XXL |ExLYWr UN <= SL |FQUWL D> ] ASoajrziidSa iris |22a~aT 20a |T22a0
[0] x : 8 £ g « 2 3] E x= c ol _ S _ 5
S13 83 : -— : © 4 o [4}
L = 52] cE >8L | >220 0 > B >< 0 62 | SEi5| SEER|S5EE 5 |§.%| SEW 5%c 3 5 £2 263 a3 a c 3 S 3c
SEQ © a EQ a EgQ|EcS o Ea ® Ec®as =a | Ss | € s GO som 6 & ZT 0|S EGGS ocEFR|oooER|oES RIESE EcEFE|SESCES
C8 5 5 oo EEE %a BS E88 eg CSV g5a0 QQ 5 @ oc YQ go>
Sege3dl|l8323cec|83cEa|lEEa®ac|Eoe|O0EEAa©bd = (I o|Qo ~om | © tg OO ™ | 82 20883 S0lwgd mer C® | Cg ¢ Nm T |e ORRND . [+] =3 MOANA |AYQRYNA lee VERA I VAIN A~ VOT "NA r-] [ng —_ — col|loco 25 [20%¢ |mof22 202d 2 ada |222 122550 @3 |]JNZw [602 yt jv vO lyve=T VVVI| vvee-— —- 2 _ — —- £ a E £ r= =] 3 ye =} — = —— a i= £2 = © = O 2 2 £ hel c £ 5 £ I 3 g 3 2 £ 12 2 oS S S o g $ | 8 = 3 £ < n Te) ‘ ] s © %: + 3 ©
Ko] ~N [32] [@] Te] 0
16 a . ol % © = A -— [e)) NO -— fe) [Ie] -— oO DIO © © on — QM = 5X2 |88% 2p |383x2|888E Xorelx
T oluX EE exX |Cage X |fidPlohXXXXA o § SS Chbxuwikxkou Ltt xousSEED e x22 BOSSSS | n0IAZZT|00OLTd2220aax
[3] x o £ © «© 2 E E g : & & 3 = |: 33
Q © o [o} To oo ] > @ © Cc >% Q= >> 2.8
SE SEEE|, SS5E|,. S9EESSE_%% £S|s _Re22|8_.SeE2|8_Ssege2ge ec |lve cclaoc ES lw ec SES55¢c 0 |ES|SGoESS|gcoES |osoaEE2FEES
SldO | FETVD|R8FTEBTL | 8 [EEC DBDS5 ggg 2|leE| 83 EEE O0O2EE|S 022 EEEDaaQo0 - he] 3 c = = —_ o mo. 0 _ 00000000 8185 [oo|gleaen]oanTa an 22222220 2193 Pre llcoanw |W OY | @yFyyyvVVVVYV ™ A : > a ll ] : : = © ; Nw Se A A Re A 23 [Zo |89anee|og8tojo ze 2222202
OF [Ye [8@onrnra|s2ganNOoyNyyvVVVVY <
Q
3 £ — = ; 5 = E @ |3 £ 3D ry = = s ped —_ he) «© Rl [le] c c he) = 0 5 o j= 2 = 2 3 E]
E |S |Z 2 2
S CA © S wh ~ [se] [<2] —
x a Do -— fe) [+)) [+2] ‘® © 0 00d x32 05 ev SIXT |RARRPD IND Xo
ALEGRE EIREEY: id Nu X | Luo XX |lwwoapwD d SlExXS|IXXxXQUS | XXEXZ g x |Xx350 oidld=230c|mdoxT l=
Q x 3 £ po pu 3 E £ -— r=] o £ £ s | 2 ; 8 88 3
[1] —1
Ss §SZE 5s 2 2: ge 5868cls E ® c®8s|l ®2Ecs SccdE o | cas |coaE 2 too oE >| 833%3|c=22eecs8|c0a02E } a— =] ® <3 £ t o
S183 |S3s|reeces|azIn®lg
L113 |€Y¢8|Cawado |ormoO yy - ™m 2°
Ke] © } -
Q
83 O-<sogn [nena lg
SHE Srmoyo jays = a 3 £ ge]
R= hu = = &
Q 2 = £ 'S) > z 5 < a o we) 2 ? 2 a £ L a £ 2 ™ < <Q x3 Qo - o
4. In vivo experiments
Compounds of Examples 1, 4, 6, 8, 9 and 10 were subjected to /n vivo testing in nude mice bearing subcutaneously growing human tumor xenograft LXFL 529.
The indigoid bisindole derivatives were applied intraperitoneally to the animals in doses and according to the schedule as described in Table 4.
Table 4 doses schedule of application activity rating Graph shown in [mg/kg/day] | [day(s}} Figure
Ex. 1 100 1-5,8-9 + Fig. 1 and 2 200 1-5,8-9 + + Fig. 1 and 2
Ex. 4 100 1-5 + + Fig. 1 and 2 300 1-5 + + Fig. 1 and 2 100 1-5,8-12,15,17,19,22 ++ Fig. 1 and 2 300 1,4,8,11,15,18,22 + + Fig. 3 and 4 100 1,4,8,11,15,18,22 Fig. 3 and 4 300 1,4,8,11,15,18,22 Fig. 3 and 4 100 1,4,8,11,15,18,22 - Fig. 3 and 4 300 1,4,8,11,15,18,22 + Fig. 3 and 4 30 1-5 .- Fig. 5 and 6 . 100 1-5 - Fig. 5 and 6 300 1-5 + Fig. 5 and 6 10 1-5, 8-12 - Fig. 7 and 8 100 1-5, 8-12 C+ Fig. 7 and 8 300 1-5, 8-12 + Fig. 7 and 8
The experiments were run for 21 or 28 days. Anti-tumor activity was evaluated comparing the median tumor volume relative to control, expressed as %T/C, wherein T is the test group and C the vehicle control group. In Table 4, anti- tumor activity is given according to an activity rate scale.
Activity rating: - inactive T/C > 50 % + tumor inhibition T/C > 25-50 % + + tumor stasis TIC < 25%
The results are further demonstrated by Figures 1 to 8.
A reduction of the body weight of the tested mice of more then 20 % by weight in general is interpreted as a toxic dose.
Claims (9)
1. Use of cell membrane penetrating indigoid bisindole derivatives for the manufacture of a medicament for the treatment of human solid tumors and metastasis thereof wherein the indigoid derivatives are selected from indigo, bis(3-phenylindol-2-yl), isoindigo and indirubin derivatives the latter - being represented by the following formula (I): r1 X @® {)] J wherein, when X represents an oxygen atom, R' represents a hydrogen atom, a halogen atom, a -NO, group, a methyl group, a sulfonamide group ‘ or SO,-NH-CH,CH,-OH; and wherein, when X represents NOH, R' represents a hydrogen atom or an iodine atom.
2. Use according to claim 1, wherein the solid tumors are selected from mammary carcinoma, melanoma, large-cell lung carcinoma, small-cell lung carcinoma, lung adenocarcinoma, colon carcinoma, bladder carcinoma, : ovarian carcinoma, pancreatic carcinoma, renal carcinoma and prostatic carcinoma.
3. Use according to claim 1 or 2, wherein the indigoid bisindole derivative is in the form of a physiologically acceptable salt.
PCT/EP00/03210 4, A substance or composition for use in a method for the treatment of human solid tumors and metastasis thereof, said substance or composition comprising a cell membrane penetrating indigoid bisindole derivate as defined in claim 1, and said method comprising administering said substance or composition.
b. A substance or composition for use in a method of treatment according to claim 4, wherein the solid tumors are selected from mammary carcinoma, melanoma, large-cell lung carcinoma, small-cell lung carcinoma, lung adenocarcinoma, colon carcinoma, bladder carcinoma, ovarian carcinoma, pancreatic carcinoma, renal carcinoma and prostatic carcinoma.
6. A substance or composition for use in a method of treatment according to claim 4 or 5, wherein the indigoid bisindole derivative is in the form of a physiologically acceptable salt.
7. Use according to claim 1, substantially as herein described and illustrated.
8. A substance or composition for use in a method of treatment according to claim 4, substantially as herein described and illustrated.
9. A new use of a compound as defined in claim 1, or a substance or composition for a new use in a method of treatment, substantially as herein described. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99106206 | 1999-04-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200108378B true ZA200108378B (en) | 2003-03-17 |
Family
ID=27799002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200108378A ZA200108378B (en) | 1999-04-12 | 2001-10-11 | Use of cell membrane penetrating indigoid bisindole derivatives. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200108378B (en) |
-
2001
- 2001-10-11 ZA ZA200108378A patent/ZA200108378B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6664285B1 (en) | Use of cell membrane penetrating indigoid bisindole derivatives | |
ES2259997T3 (en) | INDOL COMPOUNDS CONTAINING SULFONAMIDE. | |
JP2007535520A (en) | Indole and azaindole derivatives having antitumor activity | |
CA2386069C (en) | Indolyl-3-glyoxylic acid derivatives as antitumor agents | |
EP3515449B1 (en) | Quinoline derivatives as chromobox (cbx) protein inhibitors for treating cancer | |
AU2019203282A1 (en) | Dipeptide and tripeptide epoxy ketone protease inhibitors | |
JP2009501234A (en) | Treatment with hydroquinone ansamycin | |
AU2020356793A1 (en) | PH/glutathione-responsive β-carbolines/cycloketene derivatives and their preparation and application | |
Ghosh et al. | Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products | |
US7452910B2 (en) | Indolyl-3-glyoxylic acid derivatives having therapeutically valuable properties | |
ES2911183T3 (en) | Compound for selectively inhibiting kinases and use thereof | |
WO2022199547A1 (en) | 7,9-dihydropurine derivative and pharmaceutical purpose thereof | |
JPH0242098A (en) | Oligopeptides having cyclic proline like amino acid | |
EP1408960B1 (en) | Benz-indole and benzo-quinoline derivatives as prodrugs for tumour treatment | |
CN103664734B (en) | Heterocycle hydroximic acid compound and medicinal compositions thereof and application | |
ZA200108378B (en) | Use of cell membrane penetrating indigoid bisindole derivatives. | |
JP2000502351A (en) | Pharmaceutical compounds | |
US6716879B2 (en) | Methods for anti-tumor therapy | |
CN115403583A (en) | Compound for targeted degradation of FAK protein and application thereof | |
EA016052B1 (en) | N-α-(BENZYLOXYCARBONYL)-L-γ-GLUTAMYL-3-[[2-[[BIS[BIS(2-CHLOROETHYL)AMINO]PHOSPHINYL]OXY]ETHYL]-SULFONYL]-L-ALANYL-2(R)-PHENYLGLICINE OR SALT THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING THAT COMPOUND, USE THEREOF FOR TREATMENT OF CANCER AND METHOD FOR TREATMENT OF CANCER USING SAID COMPOUND | |
TWI829329B (en) | Dual inhibitor of histone deacetylase 6 and heat shock protein 90 | |
WO2021050547A1 (en) | Mitochondrial complex i inhibitors and methods of use | |
WO2022201162A1 (en) | Rnf4 targeting compounds and uses thereof | |
JPH0834789A (en) | Pyrroloindolecarboxylic ester derivative and its production | |
JP2001513775A (en) | Tripeptide and tetrapeptide pharmaceutical compounds |